| P50 | author | John D Isaacs | Q56408288 |
| P2860 | cites work | Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes | Q24674303 |
| | The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 |
| | Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 |
| | Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score | Q33563148 |
| | Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients | Q33578306 |
| | Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis? | Q33762520 |
| | Cytokine pathways and joint inflammation in rheumatoid arthritis | Q33939087 |
| | Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial | Q34559671 |
| | Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial | Q34566004 |
| | A two-step, two-signal model for the primary activation of precursor helper T cells | Q34797521 |
| | Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period | Q34896269 |
| | Therapeutic strategies for rheumatoid arthritis | Q35140855 |
| | Patient preferences for treatment of rheumatoid arthritis. | Q35553503 |
| | A review of the MHC genetics of rheumatoid arthritis. | Q35642056 |
| | T-cell regulation in rheumatoid arthritis | Q35753672 |
| | The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons | Q36810833 |
| | A unique cell surface antigen identifying lymphoid malignancies of B cell origin | Q37025725 |
| | Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. | Q37173126 |
| | Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy | Q39319086 |
| | Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept | Q40090577 |
| | CD20: a regulator of cell-cycle progression of B lymphocytes | Q40393831 |
| | Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial | Q42950968 |
| | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 |
| | American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 |
| | Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy | Q48454849 |
| | Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. | Q52853837 |
| | Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. | Q53487037 |
| | Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 |
| | Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study | Q57751326 |
| | Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis | Q57753793 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| | TNF | Q18032037 |
| P304 | page(s) | 1463-1475 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists | |
| P478 | volume | 9 | |